Table 1

General characteristics of study population (n=718)

Frequency%
Median(IQR)
(a) Demographics
Male gender60584%
Ethnicity
 Chinese58181%
 Asian (Asian other than Chinese)8712%
 White477%
 African30.4%
 Age (years, at HIV diagnosis) 37 (31–45)
(b) HIV infection and diagnosis
Mode of transmission
 Heterosexual39455%
 Man-to-man sex28039%
 Injection drug use345%
 Contaminated blood transfusion61%
 Undetermined41%
HIV-1 subtype
 CRF01_AE27038%
 B22431%
 C81%
 Others314%
 Unavailable18526%
AIDS diagnosis before treatment23933%
Late HIV diagnosis*19227%
Estimated cumulative viral load† from seroconversion to diagnosis (n=199) 8 (3–18)
(c) Pre-HAART status
Age (years) 39 (33–46)
Months from diagnosis to treatment initiation 8.67 (2.75–33.13)
CD4 count (cells/µL) 109 (29–190)
CD4:CD8 ratio‡ 0.14 (0.06–0.23)
CD8 count (cells/µL)‡ 673 (441–966)
Viral load (log10 copies/mL)§  5.15 (4.62–5.58)
Estimated cumulative viral load† from seroconversion to treatment initiation (n=199) 18 (11–29)
(d) Antiretroviral treatment and clinical outcomes
First HAART regimen
 NNRTI based18225%
 PI based13118%
 PI based with booster39755%
 Non-standard81%
Total treatment duration (months) 85.38 (63.39–117.32)
AIDS free during treatment (n=479)45695%
Highest CD4 count within 4 years¶ 476 (354–630)
Highest CD4:CD8 ratio within 4 years** 0.55 (0.39–0.76)
CD4 count ≥500/μL within 4 years¶31844%
CD4:CD8 ratio ≥0.8 within 4 years††14520%
 Deceased395%
  • *Late HIV diagnosis refers to the diagnosis of AIDS within 3 months of HIV diagnosis.

  • †Estimated cumulative viral load expressed as years×log10 viral load copies/mL.

  • ‡14 missing values.

  • §18 missing values.

  • ¶2 missing values.

  • **8 missing values.

  • ††3 missing values.

  • HAART, highly active antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.